Spruce Street Capital LP purchased a new position in shares of Athira Pharma, Inc. (NASDAQ:ATHA – Free Report) during the fourth quarter, Holdings Channel reports. The firm purchased 393,701 shares of the company’s stock, valued at approximately $2,980,000. Athira Pharma comprises about 1.0% of Spruce Street Capital LP’s holdings, making the stock its 22nd largest holding. Spruce Street Capital LP owned 0.10% of Athira Pharma at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of ATHA. Renaissance Technologies LLC raised its stake in Athira Pharma by 44.7% during the fourth quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after purchasing an additional 23,223 shares during the period. Jane Street Group LLC purchased a new position in Athira Pharma during the fourth quarter worth about $100,000. Finally, Focus Partners Wealth purchased a new position in Athira Pharma during the third quarter worth about $35,000. 57.12% of the stock is currently owned by institutional investors and hedge funds.
Athira Pharma Price Performance
Shares of ATHA stock opened at $8.22 on Tuesday. The firm’s 50-day moving average is $9.51 and its two-hundred day moving average is $7.36. Athira Pharma, Inc. has a 12 month low of $0.23 and a 12 month high of $8.36. The company has a market capitalization of $32.42 million, a PE ratio of -0.85 and a beta of 2.79.
About Athira Pharma
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.
Featured Articles
- Five stocks we like better than Athira Pharma
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding ATHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athira Pharma, Inc. (NASDAQ:ATHA – Free Report).
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
